Los Angeles Capital Management & Equity Research Inc. Lowers Holdings in Regeneron Pharmaceuticals, Inc. (REGN)

Los Angeles Capital Management & Equity Research Inc. lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,981 shares of the biopharmaceutical company’s stock after selling 1,746 shares during the quarter. Los Angeles Capital Management & Equity Research Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,955,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Sterling Investment Advisors Ltd. lifted its position in Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 28 shares during the last quarter. FNY Managed Accounts LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at $140,000. Alpha Windward LLC lifted its position in Regeneron Pharmaceuticals by 0.3% during the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 1 shares during the last quarter. IFP Advisors Inc lifted its position in Regeneron Pharmaceuticals by 33.2% during the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 96 shares during the last quarter. Finally, Wendell David Associates Inc. bought a new position in Regeneron Pharmaceuticals during the second quarter valued at $204,000. Institutional investors and hedge funds own 67.96% of the company’s stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 433.45 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $325.35 and a 12 month high of $543.55. The stock has a market cap of $45.96 billion, a P/E ratio of 43.48 and a beta of 1.65. The stock has a 50 day moving average of $472.80 and a 200-day moving average of $445.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.82 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.90 EPS for the current fiscal year.

In other news, major shareholder Sanofi bought 166,415 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The shares were purchased at an average cost of $480.93 per share, for a total transaction of $80,033,965.95. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert E. Landry sold 189 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the sale, the chief financial officer now owns 10,099 shares in the company, valued at $5,060,204.94. The disclosure for this sale can be found here. Insiders have sold 99,543 shares of company stock worth $47,831,369 over the last 90 days. Insiders own 10.40% of the company’s stock.

Several equities analysts have commented on the stock. J P Morgan Chase & Co reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 15th. Robert W. Baird lowered shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price objective for the company. in a research report on Tuesday, August 8th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $472.00 price objective (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 price objective for the company in a research report on Wednesday, August 9th. Finally, Leerink Swann reiterated an “outperform” rating and set a $580.00 price objective (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and an average target price of $491.43.

ILLEGAL ACTIVITY WARNING: “Los Angeles Capital Management & Equity Research Inc. Lowers Holdings in Regeneron Pharmaceuticals, Inc. (REGN)” was first posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://transcriptdaily.com/2017/09/17/los-angeles-capital-management-equity-research-inc-lowers-holdings-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply